Comparison and evaluation of different effects of three alpha-Glucosidase inhibitors on lowering blood sugar and body weight in Japanese obese patients with type 2 diabetes

Comparison and evaluation of different effects of three alpha-Glucosidase inhibitors on lowering blood sugar and body weight in Japanese obese patients with type 2 diabetes - Nippon Medical School Group:Clinical Usefulness Research of alpha-glucosidase inhibitor Effect on Type 2 Diabetes Mellitus with Obesity (N-CURE Study)

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000006465

Enrollment

Registered

2011-10-04

Start date

2007-10-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Type 2 Diabetes Mellitus

Interventions

Miglitol 150mg/day 12weeks Voglibose 0.9mg/day 12weeks Acarbose 300mg/day 12weeks Non-alpha-GI-treated 12weeks

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Japanese patients of both sexes, age 40 or older who were under the care of one of the study centers and who were obese patients with type 2 diabetes with an HbA1c of 6.4% to 8.4% (NGSP) and a body mass index (BMI) of 25 kg/m2 or above.

Exclusion criteria

Exclusion criteria: Patients on insulin therapy and patients with a serious hepatic, renal, or cardiac disease

Design outcomes

Primary

Measure	Time frame
HbA1c,1.5-AG,Body Weight,BMI	—

Secondary

Measure	Time frame
FPG,Serum Insulin,HOMA-IR,Adiponectin,Leptin, Questionnaires(digestive symptoms,appetite,drug compliance)	—

Countries

Japan

Contacts

Public ContactShinichi Oikawa

Nippon Medical School Division of Endocrinology and Metabolism, Department of Medicine

shinichi@nms.ac.jp03-3822-2131

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026